key: cord-0968423-aorlza66
authors: Mori, Jun; Oudit, Gavin Y.; Lopaschuk, Gary D.
title: SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism
date: 2020-07-01
journal: Am J Physiol Endocrinol Metab
DOI: 10.1152/ajpendo.00219.2020
sha: 7188b8145dcbd5d861b7546c3b397f75d745bb87
doc_id: 968423
cord_uid: aorlza66

The COVID-19 pandemic, caused by the novel coronavirus, SARS-CoV-2, is threating our health systems and daily lives and is responsible for causing substantial morbidity and mortality. In particular, aged individuals and individuals with comorbidities, including obesity, diabetes mellitus, and hypertension, have significantly higher risks of hospitalization and death than normal individuals. The renin-angiotensin system (RAS) plays a pivotal role in the pathogenesis of diabetes mellitus, obesity, and hypertension. Angiotensin-converting enzyme 2 (ACE2), belonging to the RAS family, has received much attention during this COVID-19 pandemic, owing to the fact that SARS-CoV-2 uses ACE2 as a receptor for cellular entry. Additionally, the RAS greatly affects energy metabolism in certain pathological conditions, including cardiac failure, diabetes mellitus, and viral infections. This article discusses the potential mechanisms by which SARS-CoV-2 modulates the RAS and energy metabolism in individuals with obesity and diabetes mellitus. The article aims to highlight the appropriate strategies for combating the COVID-19 pandemic in the clinical setting and emphasize on the areas that require further investigation in relation to COVID-19 infections in patients with obesity and diabetes mellitus from the viewpoint of endocrinology and metabolism.

The current COVID-19 pandemic, caused by the novel coronavirus, SARS-CoV-2, is severely compromising health care systems worldwide and altering the course of our daily lives. Despite the infected individuals being treated, there is a rising concern that patients with chronic diseases (including cardiovascular diseases, hypertension, diabetes mellitus, and severe obesity) have an increased risk of severe SARS-CoV-2 infections. This notion is based on the fact that these comorbidities are most frequent in patients with severe SARS-CoV-2 infections (5, 20, 34) . Diabetes mellitus is an independent risk factor for the severity of SARS-CoV-2 infections (6) . Angiotensin-converting enzyme 2 (ACE2) has gathered much attention in the present SARS-CoV-2 pandemic, owing to the fact that SARS-CoV-2 virus uses ACE2 as a receptor for cellular entry (8, 33) . ACE inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) are frequently prescribed to patients with cardiovascular diseases, hypertension, and diabetes mellitus, and it has been reported that these agents upregulate the expression and/or function of ACE2 (3). Statins and thia-zolidinediones also upregulate the expression and/or function of ACE2 (27, 36) . Therefore, there has been a rising concern regarding the administration of drugs that upregulate the expression of ACE2 to patients with COVID-19. Despite such theoretical concerns, the clinical data as to whether ACEIs and ARBs increase susceptibility of SARS-CoV-2 is lacking, and these drugs are clearly beneficial for the patients with cardiac disease, chronic kidney disease, and hypertension (28) . Several scientific societies, including the American College of Cardiology, the American Heart Association, and the American Society of Hypertension, have recommended the continued use of these drugs in patients with COVID-19 infections (2). The COVID-19 pandemic has caused turmoil in the clinical scenario and imposes as an additional challenge to patients with endocrine diseases and diabetes. Endocrinologists need to understand the precise mechanism by which the renin-angiotensin system (RAS), including ACE2, interacts with SARS-CoV-2 for treating patients with endocrine diseases who are at an increased risk of SARS-CoV-2 infections. Understanding the mechanisms and physiology that increase the risk of SARS-CoV-2 infections is necessary for providing adequate therapy for patients with endocrine diseases and also for promoting both basic and clinical research in the field of endocrinology and metabolism. This article discusses the mechanism by which SARS-CoV-2 affects the RAS and energy metabolism, especially in obesity patients, with or without diabetes.

The classical RAS is a hormonal system that regulates blood pressure as well as fluid and electrolyte homeostasis. Angiotensinogen, the principal precursor of the RAS, is produced from the liver and is sequentially cleaved into angiotensin I (Ang I) and angiotensin II (Ang II) by renin and ACE, respectively.

ACE2, located on the surface of endothelial cells, is a carboxypeptidase that hydrolyzes Ang I (Ang 1-10) and Ang II (Ang 1-8) to Ang 1-9 and Ang 1-7, respectively (23) . Ang II mediates its physiological effects through the G protein-coupled receptors angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). The primary effects of Ang II, including inflammation, vasoconstriction, fibrosis, and the production of reactive oxygen species (ROS), are mediated via AT1R (Fig. 1) . Additionally, ACE2 counteracts the ACE-Ang II-AT1R axis via the Mas receptor, which is specific to Ang 1-7 ( Fig. 1 ). ACE2 has numerous beneficial effects, including cardioprotective, nephroprotective, antidiabetic, and antioxidative effects (9, 21, 22, 37) . The binding of Ang 1-7 to the Mas receptor mediates the activation of phosphatidylinositol 3-kinase (PI3K), which subsequently alters the immune system by upregulating the phosphatidylinositol signaling pathway (12, 18) . The balance between ACE/Ang II/AT1R and ACE2/Ang 1-7/ MasR is crucial for maintaining normal health (30) . ADAM17 plays a key role in maintaining the balance between ACE/Ang II/AT1R and ACE2/Ang 1-7/MasR by mediating the shedding of the ectodomain of ACE2.

ACE2 plays a crucial role in viral entry into host cells and subsequent viral proliferation, as the SPIKE protein (S protein), located on the viral coat of SARS-CoV-2, binds ACE2 and mediates cellular entry ( Fig. 2) (29) . ACE2 is ubiquitously expressed, and the expression of ACE2 is highest in the gut, kidneys, adipose tissue, heart, and lungs (38) . The ubiquitous expression of ACE2 is consistent with various symptoms of SARS-CoV-2 infections, such as respiratory symptoms, gastrointestinal symptoms, acute cardiac damage including arrhythmia, liver, and kidney damage (4, 35) . Some studies have warned against the usage of ACE2 stimulating drugs, including ACEIs and ARBs, and recommend the discontinuation of these drugs. On the other hand, in diabetic patients, the expression of the ACE2 protein is increased in the kidneys, lungs, heart, and pancreas (14, 26, 32) , indicating that the expression of ACE2 is upregulated regardless of drug intake. The upregulation in the expression of ACE2 could be associated with the increased susceptibility of obese and diabetic individuals to SARS-CoV-2 infections, since SARS-CoV-2 enters the cell by binding to ACE2. However, we cannot simply say the upregulation of ACE2 is detrimental. ACE2 serves as an alternative protective arm of the ACE2-Ang1-7-Mas receptor axis, which counteracts the ACE-Ang II-AT1 receptor axis that is activated under pathological conditions. The initial detrimental effects of viral infections result from a loss of the protective effects of ACE2 (31) . An increase in the levels of Ang II triggers vasoconstriction, inflammation, cell proliferation, and fibrosis. ACE2 cleaves Ang II into Ang 1-7, which induces the counteractive effect of the Ang II-AT1 receptor axis via the Mas receptor. The ACE2-Ang 1-7-Mas receptor axis has two pathways, one of which decreases the levels of Ang II, and the other which induces the counteractive effects of the Ang II-AT1 receptor axis (4). ACE2 is not only an entry receptor for the SARS-CoV-2 virus but also protects against the pathogenic effects of RAS and the ACE-Ang II-AT1R axis.

Obese subjects, with or without diabetes, have a defective immune response owing to chronic inflammation (1). In fact, obesity was reported to be an independent risk factor for hospitalization and death due to the H1N1 Influenza A virus (13) . The production of Ang II and several proinflammatory cytokines, including TNF␣, monocyte chemoattractant protein-1 (MCP-1), and IL-6 is higher in obese patients than in normal individuals (24) . Both Ang II and proinflammatory cytokines are primarily regulated by ADAM17, a type I transmembrane metalloproteinase. The expression of ACE2 in tis- (7). This leads to a shift from the ACE2-Ang 1-7-MasR axis to the ACE-Ang II-AT1R axis. This shift augments RAS effects on various pathological conditions, including inflammation and the production of ROS (30) . Another potential mechanism increasing the susceptibility for SARS-CoV-2 in patients with diabetes is proposed, such as impaired T cell function and susceptibility to elevated cytokines (19) . Obesity also alters T cell response to viral infection. RAS-involved production of cytokines and impaired immune system might increase susceptibility to SARS-CoV-2 in obese individuals with or without diabetes.

Viral infection in mammalian cells affects cellular metabolism by inducing a switch in the metabolism from oxidative phosphorylation to glycolysis, which decreases ATP production (25) . For instance, the H1N1 viral infection decreases the activity of the pyruvate dehydrogenase complex (PDC) and ATP production by upregulating pyruvate dehydrogenase kinase 4 (PDK4), which is a critical player in regulating carbohydrate oxidation via PDC phosphorylation. In diabetes, the activity of PDC is decreased by PDK, which phosphorylates and inactivates PDC (11) . Interestingly, Ang II causes insulin resistance by suppressing the activity of PDC via the phosphorylation and acetylation of PDC (15, 16) . The uncoupling between glycolysis and oxidative phosphorylation, that is,

Ang II Ang 1-7 ADAM17 SARS-CoV-2 glucose oxidation, produces protons via the hydrolysis of ATP derived from glycolysis, leading to intracellular acidosis and cellular dysfunction (17) . Ang II also causes impaired mitochondrial function (17) . Therefore, we hypothesize that SARS-CoV-2 infections induce an imbalance in the RAS, downregulate the ACE2-Ang 1-7-MasR axis, and upregulate the ACE-Ang II-AT1R axis. The imbalance in the RAS reduces the activity of PDC, which subsequently perturbs energy metabolism in cells (Fig. 3) . Obese individuals, with or without diabetes, have insulin resistance, which is associated with an increase in the activity of PDK that phosphorylates and inactivates PDH. Therefore, SARS-CoV-2 infections exacerbate the perturbation in energy metabolism in obese individuals with or without diabetes.

In addition to respiratory complications, SARS-CoV-2 infections induce multiorgan dysfunctions by perturbating the RAS and energy metabolism. Restoring the balance in the RAS and energy metabolism could be crucial to reducing disease severity and the mortality of patients with COVID-19, and especially obese patients, with or without diabetes. Further epidemiological investigations are necessary for clarifying whether the susceptibility to SARS-CoV-2 infections and the severity of COVID-19 is higher in obese individuals with or without diabetes in comparison with those of normal individuals. Furthermore, since the individuals affected during the SARS outbreak in 2002 have been reported to have a high risk of long-term endocrine sequelae (10), we need to investigate whether individuals infected with SARS-CoV-2 have endocrine sequelae. 

Impact of obesity and metabolic syndrome on immunity

Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence that RAS blockers facilitate SARS-CoV-2 entry into cells

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2

Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

Diabetes is a risk factor for the progression and prognosis of COVID-19

Modulation of TNF-␣-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-␣ production and facilitates viral entry

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue

Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)

Myocardial fatty acid metabolism in health and disease

Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease

Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity

Impact of the reninangiotensin system on cardiac energy metabolism in heart failure

ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4

Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction

Angiotensin 1-7 stimulates brown adipose tissue and reduces diet-induced obesity

COVID-19 pandemic, coronaviruses, and diabetes mellitus

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Human recombinant ACE2 reduces the progression of diabetic nephropathy

• www.ajpendo.org enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling

Role of the ace2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure

Individuals with obesity and type 2 diabetes have additional immune dysfunction compared with obese individuals who are metabolically healthy

Metabolic effects of influenza virus infection in cultured animal cells: Intra-and extracellular metabolite profiling

Characterization of ACE and ACE2 expression within different organs of the NOD mouse

Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Angiotensin converting enzyme 2: a double-edged sword

SARS coronavirus entry into host cells through a novel clathrin-and caveolaeindependent endocytic pathway

Regulation of urinary ACE2 in diabetic mice

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection